Research progress in diagnosis and treatment of renal light/heavy chain deposition disease

doi:10.3877/cma.j.issn.2095-3216.2014.02.009

Abstract

Abstract:

Light/heavy chain deposition disease is a clinically rare disease in which kidney is the most commonly affected organ,and usually manifested heavy proteinuria and renal insufficiency. Blood/urine free light chain ratio is of diagnostic value. Renal pathology is an important method for diagnosis of kidneyinvolved light/heavy chain deposition disease in which light microscopy, electron microscopy, and immunopathology are all indispensable for the diagnosis. Nodular glomerulosclerosis is a typical pathological change under light microscope. Autologous stem cell transplantation is considered conducive to improve the prognosis of patients with renal involvement. Here, the research progress in the pathogenesis, diagnosis and treatment, as well as prognosis of light/heavy chain deposition disease has been reviewed.

Key words: Light/heavy chain deposition disease, Nodular glomerulosclerosis, Autologous stem cell transplantation

Li Li, Fang Liu. Research progress in diagnosis and treatment of renal light/heavy chain deposition disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(02): 104-107.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.02.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I02/104

Figures/Tables 1

References 31

1	Antonovych TT,Lin RC, Parrish E. Light chain deposits in multiple myeloma [J]. Lab Invest,1974,30:370A.
2	Randall RE, Williamson WC Jr, Mullinax F, et al. Manifestations of systemic light chain deposition [J]. Am J Med, 1976, 60(2):293-299.
3	Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis [J]. Ann Intern Med,1990,112(6):455-464.
4	Aucouturier P, Khamlichi AA, Touchard G, et al. Heavy-chain deposition disease [ J]. N Engl J Med, 1993, 329 (19):1389-1393.
5	Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum [J]. J Am Soc Nephrol,2001,12(7):1482-1492.
6	Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution [J]. Clin J Am Soc Nephrol, 2012, 7(2):231-239.
7	Bruneval P,Foidart JM,Nochy D,et al. Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus [J]. Hum Pathol, 1985,16(5):477-484.
8	Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage [J]. Kidney Int,2005,68(4):1590-1603.
9	Keeling J, Teng J, Herrera GA. AL-amyloidosis and lightchain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells[J]. Lab Invest,2004,84(10):1322-1338.
10	Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light(heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy [J]. Clin J Am Soc Nephrol,2006,1(6):1342-1350.
11	Khurana R, Gillespie JR, Talapatra A, et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates [J]. Biochemistry, 2001, 40(12): 3525-3535.
12	Denoroy L, Dé ret S, Aucouturier P. Overrepresentation of the V kappa IV subgroup in light chain deposition disease [J]. Immunol Lett,1994,42(1-2):63-66.
13	Moulin B, Deret S, Mariette X, et al. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1 [J]. J Am Soc Nephrol,1999,10(3):519-528.
14	Kambham N, Markowitz GS, Appel GB, et al. Heavy chain deposition disease: the disease spectrum [J]. Am J Kidney Dis,1999,33(5):954-962.
15	Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders[J]. Semin Nephrol,2002,22(4):319-330.
16	Rathi M, Ramachandran R, Kohli HS, et al. An unusual cause of gross hematuria and renal dysfunction in a young male [J], Indian J Nephrol,2013,23(5):371-374.
17	Heilman RL,Velosa JA,Holley KE,et al. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease [J]. Am J Kidney Dis,1992,20(1):34-41.
18	Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: A poorly recognized pattern of renal disease in patients with plasma cell dyscrasia [J]. Arch Pathol Lab Med, 2006, 130(2):165-169.
19	Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine [J]. Clin Chem,2009,55(3):499-504.
20	Gerth J, Sachse A, Busch M, et al. Screening and differential diagnosis of renal light chain-associated diseases[J]. Kidney Blood Press Res,2012,35(2):120-128.
21	Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement:clinical characteristics and prognostic factors [J]. Am J Kidney Dis,2003,42(6):1154-1163.
22	Komatsuda A, Maki N, Wakui H, et al. Development of systemic lambda-light chain amyloidosis in a patient with gamma-heavy chain deposition disease during long-term follow-up [J]. Nephrol Dial Transplant,2005,20(2):434-437.
23	Nakatsuka A, Maeshima Y, Sarai A, et al. A case of monoclonal immunoglobulin light- and heavy-chain deposition disease exhibiting atypical deposition with fibrillary structures,successfully treated with chemotherapy [J]. Clin Nephrol,2005,64(3):221-227.
24	Weichman K, Dember LM, Prokaeva T, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation [J]. Bone Marrow Transplant,2006,38(5):339-343.
25	Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease [J]. Kidney Int,2004,65(2):642-648.
26	Firkin F, Hill PA, Dwyer K, et al. Reversal of dialysis dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation [J]. Am J Kidney Dis,2004,44(3):551-555.
27	Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease-diagnosis and treatment [J]. Clin J Am Soc Nephrol,2007,2(4):858-867.
28	Gerth J, Sigusch H, Illner N, et al. Renal manifestations of light chain associated diseases-epidemiology and prognosis [J]. Dtsch Med Wochenschr,2013,138(7):305-312.
29	Hassoun H, Flombaum C, D'Agati VD, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease [J].Bone Marrow Transplant,2008,42(6):405-412.
30	Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease [J]. Am J Kidney Dis,2004,43(1):147-153.
31	Stratta P, Gravellone L, Cena T, et al. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience [J]. Crit Rev Oncol Hematol,2011,79(1):31-42.

Please choose a citation manager

Content to export